HBeAg-negative chronic hepatitis B: Why do I treat my patients with nucleos(t)ide analogues

Research output: Contribution to journalArticle

Abstract

Antiviral therapy is aimed to persistently suppress hepatitis B virus (HBV) to prevent liver complications and improve survival and long-term administration of nucleos(t)ide analogues represents an attractive treatment strategy. Five oral analogues are available, and all inhibit viral replication in most patients during the first year of therapy. By converse, long-term monotherapy is associated to high rates of resistance with lamivudine, and intermediate rates with Adefovir and Telbivudine. Third-generation analogues such as Entecavir and Tenofovir may efficiently inhibits viral replication in most patient for many years as they couple potency and high genetic barrier. In patients developing drug-resistance, specific rescue protocols based upon 'early add-on' have been developed to rapidly and efficiently control viral replication. In cirrhotics, long-term effective analog-based therapy prevented clinical decompensation for many years, but not liver cancer development. Long-term administration of NUCs, either as a monotherapy or as a sequential combination, inhibits HBV replication in most HBeAg-negative patients for at least 5 years, preventing clinical decompensation in cirrhotics.

Original languageEnglish
Pages (from-to)130-132
Number of pages3
JournalLiver International
Volume29
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 2009

Fingerprint

Hepatitis B e Antigens
Chronic Hepatitis B
Tenofovir
Hepatitis B virus
Lamivudine
Therapeutics
Liver Neoplasms
Virus Replication
Drug Resistance
Antiviral Agents
Survival
Liver

Keywords

  • Chronic hepatitis
  • HBV-DNA
  • Nucleos(t)ide analogue
  • Resistance

ASJC Scopus subject areas

  • Hepatology

Cite this

HBeAg-negative chronic hepatitis B : Why do I treat my patients with nucleos(t)ide analogues. / Lampertico, Pietro; Colombo, Massimo.

In: Liver International, Vol. 29, No. SUPPL. 1, 2009, p. 130-132.

Research output: Contribution to journalArticle

@article{c080ab643e51454dad6620cd3ae63f46,
title = "HBeAg-negative chronic hepatitis B: Why do I treat my patients with nucleos(t)ide analogues",
abstract = "Antiviral therapy is aimed to persistently suppress hepatitis B virus (HBV) to prevent liver complications and improve survival and long-term administration of nucleos(t)ide analogues represents an attractive treatment strategy. Five oral analogues are available, and all inhibit viral replication in most patients during the first year of therapy. By converse, long-term monotherapy is associated to high rates of resistance with lamivudine, and intermediate rates with Adefovir and Telbivudine. Third-generation analogues such as Entecavir and Tenofovir may efficiently inhibits viral replication in most patient for many years as they couple potency and high genetic barrier. In patients developing drug-resistance, specific rescue protocols based upon 'early add-on' have been developed to rapidly and efficiently control viral replication. In cirrhotics, long-term effective analog-based therapy prevented clinical decompensation for many years, but not liver cancer development. Long-term administration of NUCs, either as a monotherapy or as a sequential combination, inhibits HBV replication in most HBeAg-negative patients for at least 5 years, preventing clinical decompensation in cirrhotics.",
keywords = "Chronic hepatitis, HBV-DNA, Nucleos(t)ide analogue, Resistance",
author = "Pietro Lampertico and Massimo Colombo",
year = "2009",
doi = "10.1111/j.1478-3231.2008.01931.x",
language = "English",
volume = "29",
pages = "130--132",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - HBeAg-negative chronic hepatitis B

T2 - Why do I treat my patients with nucleos(t)ide analogues

AU - Lampertico, Pietro

AU - Colombo, Massimo

PY - 2009

Y1 - 2009

N2 - Antiviral therapy is aimed to persistently suppress hepatitis B virus (HBV) to prevent liver complications and improve survival and long-term administration of nucleos(t)ide analogues represents an attractive treatment strategy. Five oral analogues are available, and all inhibit viral replication in most patients during the first year of therapy. By converse, long-term monotherapy is associated to high rates of resistance with lamivudine, and intermediate rates with Adefovir and Telbivudine. Third-generation analogues such as Entecavir and Tenofovir may efficiently inhibits viral replication in most patient for many years as they couple potency and high genetic barrier. In patients developing drug-resistance, specific rescue protocols based upon 'early add-on' have been developed to rapidly and efficiently control viral replication. In cirrhotics, long-term effective analog-based therapy prevented clinical decompensation for many years, but not liver cancer development. Long-term administration of NUCs, either as a monotherapy or as a sequential combination, inhibits HBV replication in most HBeAg-negative patients for at least 5 years, preventing clinical decompensation in cirrhotics.

AB - Antiviral therapy is aimed to persistently suppress hepatitis B virus (HBV) to prevent liver complications and improve survival and long-term administration of nucleos(t)ide analogues represents an attractive treatment strategy. Five oral analogues are available, and all inhibit viral replication in most patients during the first year of therapy. By converse, long-term monotherapy is associated to high rates of resistance with lamivudine, and intermediate rates with Adefovir and Telbivudine. Third-generation analogues such as Entecavir and Tenofovir may efficiently inhibits viral replication in most patient for many years as they couple potency and high genetic barrier. In patients developing drug-resistance, specific rescue protocols based upon 'early add-on' have been developed to rapidly and efficiently control viral replication. In cirrhotics, long-term effective analog-based therapy prevented clinical decompensation for many years, but not liver cancer development. Long-term administration of NUCs, either as a monotherapy or as a sequential combination, inhibits HBV replication in most HBeAg-negative patients for at least 5 years, preventing clinical decompensation in cirrhotics.

KW - Chronic hepatitis

KW - HBV-DNA

KW - Nucleos(t)ide analogue

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=59149092224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59149092224&partnerID=8YFLogxK

U2 - 10.1111/j.1478-3231.2008.01931.x

DO - 10.1111/j.1478-3231.2008.01931.x

M3 - Article

C2 - 19207976

AN - SCOPUS:59149092224

VL - 29

SP - 130

EP - 132

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - SUPPL. 1

ER -